BioCentury | Oct 15, 2012
Clinical News

TS01: Phase I started

...ascending-doses of TS01 with or without a C1 esterase inhibitor in 50-70 healthy male volunteers. Thrombolytic Science International LLC...
BioCentury | Mar 22, 2012
Tools & Techniques

Monkeys bridge the stroke gap

...from Schering AG , now part of Bayer. Victor Gurewich, cofounder and scientific director of Thrombolytic Science International LLC...
...Harvard Medical School and director of Beth Israel Deaconess Medical Center 's Vascular Research Laboratory. Thrombolytic Science's...
...Inc. , Toronto, Ontario, Canada Paion AG (Xetra:PA8), Aachen, Germany Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Thrombolytic Science International LLC...
BioCentury | Feb 6, 2012
Product Development

Specifying stroke

...trials in the '80s and '90s, according to Alexis Wallace, president, CEO and co-founder of Thrombolytic Science...
...product also is more stable than tPA because M5 is inert until reaching a clot. Thrombolytic Science...
...South San Francisco, Calif. Harvard Medical School, Cambridge, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Thrombolytic Science International LLC...
BioCentury | Jan 18, 2012
Financial News

Thrombolytic Science raises $5 million

...In 2010, the company raised $2.5 million in seed funding from the same angel investor. Thrombolytic Science's...
Items per page:
1 - 4 of 4
BioCentury | Oct 15, 2012
Clinical News

TS01: Phase I started

...ascending-doses of TS01 with or without a C1 esterase inhibitor in 50-70 healthy male volunteers. Thrombolytic Science International LLC...
BioCentury | Mar 22, 2012
Tools & Techniques

Monkeys bridge the stroke gap

...from Schering AG , now part of Bayer. Victor Gurewich, cofounder and scientific director of Thrombolytic Science International LLC...
...Harvard Medical School and director of Beth Israel Deaconess Medical Center 's Vascular Research Laboratory. Thrombolytic Science's...
...Inc. , Toronto, Ontario, Canada Paion AG (Xetra:PA8), Aachen, Germany Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Thrombolytic Science International LLC...
BioCentury | Feb 6, 2012
Product Development

Specifying stroke

...trials in the '80s and '90s, according to Alexis Wallace, president, CEO and co-founder of Thrombolytic Science...
...product also is more stable than tPA because M5 is inert until reaching a clot. Thrombolytic Science...
...South San Francisco, Calif. Harvard Medical School, Cambridge, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Thrombolytic Science International LLC...
BioCentury | Jan 18, 2012
Financial News

Thrombolytic Science raises $5 million

...In 2010, the company raised $2.5 million in seed funding from the same angel investor. Thrombolytic Science's...
Items per page:
1 - 4 of 4